altinicline

altinicline

An alpha-4, beta-2 nicotinic acetylcholine receptor agonist which stimulates dopamine and acetylcholine release in the brain. Altinicline was being developed for managing motor, affective and cognitive changes of Parkinson's disease, but failed in phase-2 clinical trials.
References in periodicals archive ?
The first study, 201, was a parallel group, placebo controlled, multiple dose study over four weeks of oral dosing primarily to assess the safety and tolerability and secondarily the efficacy of altinicline against both motor and cognitive symptoms in early stage PD patients who were not currently receiving dopaminergic therapy.
The second study, 202, was a crossover design examining acute motor and cognitive performance over an eight hour period in which later stage patients received either placebo or one of three doses of altinicline in random order along with half of their normally effective dose of L-DOPA on each of four treatment days.
SIBIA's Chief Scientific Officer, reported, "In these studies we found altinicline to be safe in the regimen used, and we defined tolerability over a broad dose range.